Altimmune, Inc.

NasdaqGM:ALT Stock Report

Market Cap: US$453.1m

Altimmune Valuation

Is ALT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALT?

Key metric: As ALT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ALT. This is calculated by dividing ALT's market cap by their current book value.
What is ALT's PB Ratio?
PB Ratio3.4x
BookUS$133.38m
Market CapUS$453.06m

Price to Book Ratio vs Peers

How does ALT's PB Ratio compare to its peers?

The above table shows the PB ratio for ALT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.9x
KROS Keros Therapeutics
0.8x-1.0%US$418.0m
MREO Mereo BioPharma Group
6.1x60.7%US$444.6m
LENZ LENZ Therapeutics
3.2x44.3%US$693.6m
QURE uniQure
13.6x50.5%US$757.7m
ALT Altimmune
3.4x27.6%US$453.1m

Price-To-Book vs Peers: ALT is good value based on its Price-To-Book Ratio (3.4x) compared to the peer average (5.9x).

Price to Book Ratio vs Industry

How does ALT's PB Ratio compare vs other companies in the US Biotechs Industry?

68 CompaniesPrice / BookEstimated GrowthMarket Cap
LYEL Lyell Immunopharma
0.3x-13.7%US$178.25m
NKTX Nkarta
0.4x-9.8%US$155.96m
MGX Metagenomi
0.4x-20.8%US$97.68m
ACET Adicet Bio
0.4x3.1%US$81.73m
ALT 3.4xIndustry Avg. 1.7xNo. of Companies78PB01.63.24.86.48+
68 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ALT is expensive based on its Price-To-Book Ratio (3.4x) compared to the US Biotechs industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is ALT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.37
US$22.25
+249.3%
22.1%US$28.00US$12.00n/a8
Feb ’26US$6.64
US$22.25
+235.1%
22.1%US$28.00US$12.00n/a8
Jan ’26US$7.21
US$22.86
+217.0%
21.7%US$28.00US$12.00n/a7
Dec ’25US$8.57
US$21.25
+148.0%
29.6%US$28.00US$10.00n/a8
Nov ’25US$6.74
US$20.57
+205.2%
31.4%US$28.00US$10.00n/a7
Oct ’25US$6.29
US$20.57
+227.0%
31.4%US$28.00US$10.00n/a7
Sep ’25US$6.70
US$20.57
+207.0%
31.4%US$28.00US$10.00n/a7
Aug ’25US$6.09
US$20.57
+237.8%
31.4%US$28.00US$10.00n/a7
Jul ’25US$7.20
US$20.57
+185.7%
31.4%US$28.00US$10.00n/a7
Jun ’25US$7.51
US$20.57
+173.9%
31.4%US$28.00US$10.00n/a7
May ’25US$7.07
US$21.86
+209.2%
35.5%US$35.00US$11.00n/a7
Apr ’25US$10.23
US$21.25
+107.7%
34.6%US$35.00US$12.00n/a8
Mar ’25US$12.09
US$21.75
+79.9%
31.1%US$35.00US$13.00n/a8
Feb ’25US$9.88
US$21.75
+120.1%
31.1%US$35.00US$13.00US$6.648
Jan ’25US$11.25
US$22.29
+98.1%
30.8%US$35.00US$15.00US$7.217
Dec ’24US$3.57
US$21.29
+496.2%
38.6%US$35.00US$8.00US$8.577
Nov ’24US$2.45
US$20.00
+716.3%
40.1%US$35.00US$10.00US$6.747
Oct ’24US$2.60
US$21.29
+718.7%
32.7%US$35.00US$15.00US$6.297
Sep ’24US$2.65
US$19.38
+631.1%
42.6%US$35.00US$6.00US$6.708
Aug ’24US$3.17
US$24.63
+676.8%
50.4%US$50.00US$6.00US$6.098
Jul ’24US$3.53
US$24.63
+597.6%
50.4%US$50.00US$6.00US$7.208
Jun ’24US$4.15
US$25.13
+505.4%
49.2%US$50.00US$6.00US$7.518
May ’24US$4.92
US$26.25
+433.5%
46.3%US$50.00US$6.00US$7.078
Apr ’24US$4.22
US$26.25
+522.0%
46.3%US$50.00US$6.00US$10.238
Mar ’24US$12.05
US$29.38
+143.8%
29.7%US$50.00US$20.00US$12.098
Feb ’24US$13.78
US$29.13
+111.4%
30.2%US$50.00US$20.00US$9.888
Analyst Price Target
Consensus Narrative from 8 Analysts
US$22.25
Fair Value
71.4% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 11:05
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Altimmune, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Joshua SchimmerEvercore ISI
Liisa BaykoEvercore ISI